French Navy strengthens anti-submarine warfare capabilities with SonoFlash sonobuoy from Thales
18.3.2021 14:54:00 EET | Business Wire | Press release
The French Navy has selected the SonoFlash new-generation sonobuoy from Thales. Unveiled at the Euronaval show in October 2018, SonoFlash will enable France to reach its strategic capability goal for acoustic sensors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005484/en/
Artist’s impression of a SonoFlash sonobuoy at sea © Thales
The threat posed by submarines is evolving rapidly. Three decades ago, only the superpowers had a true undersea warfare capability, but numerous countries now deploy modern submarine fleets. At the same time, forces increasingly operate in littoral waters, which are much more complex for sonar systems, rather than in the relative certainty of open-ocean environments.
Responding to this evolving threat environment, Thales developed the SonoFlash buoy, a new-generation sonobuoy with an unequalled performance-to-mass ratio that builds on decades of expertise in sonars and acoustic sensors to offer an ambitious new solution.
Its innovative design and advanced technology include a number of key features to deliver unrivalled performance. Today's sonobuoys are either passive or active. By contrast, the SonoFlash buoy offers the best of both modes, combining a powerful, optimised low-frequency transmitter with a high-directivity passive receiver. With the combination of these two capabilities, and the added advantage of long endurance, the SonoFlash buoy is suitable for a wide array of deployment scenarios.
Fully compatible with the other families of Thales sonars, the SonoFlash buoy offers high tactical flexibility and opens up promising new opportunities for multistatic operation. Coupled with the FLASH dipping sonar, for example, the SonoFlash buoy enables an aircraft to expand its coverage area and respond with greater agility to evasive manoeuvres by a submarine. Thanks to its digitised signal and optimal communication range, the SonoFlash buoy data can be readily exploited by any piloted or remotely piloted aircraft, naval vessel or shore centre equipped with a sonobuoy processing system.
The French Navy will be the first operational user of the SonoFlash buoy, which will be deployed by the modernised Atlantique 2 maritime patrol aircraft and NH90 Caiman tactical transport helicopters. It will be delivered to the Navy from 2025 and could be available in export markets to equip all modern maritime patrol aircraft and helicopters as well as all types of unmanned platforms, including autonomous surface vehicles and rotary-wing (VTOL) and fixed-wing UAVs equipped with a suitable multi-sonobuoy dispenser.
Manufactured in France with a network of SMEs such as TELERAD, SelhaGroup and Realmeca, the SonoFlash buoy relies on Thales’s expertise in acoustic sensor technology to contribute to France’s desire for independence in strategic industries.
“Thales has packed 10 years of innovation in hardware and digital technologies into a tube measuring 91.4 cm long and 12.3 cm in diameter. SonoFlash extends the range of a naval force's anti-submarine warfare operations, outclassing all other sonobuoys in the market today and offering a versatile and easy-to-deploy solution for tracking submarines from any piloted or remotely piloted aircraft, frigate or unmanned surface vehicle. We are grateful to the DGA and the Navy for the trust they have placed in us and delighted to be working with French partner SMEs to bring this project to a successful conclusion and restore France's sovereign capabilities in sonobuoys.” Alexis Morel, VP Underwater Systems, Thales.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005484/en/
Contact information
Thales, Media Relations
Land and Naval Defence
Faïza Zaroual
+33 (0)7 64 25 99 31
faiza.zaroual@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 13:07:00 EEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 02:17:00 EEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors1.5.2026 00:16:00 EEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’30.4.2026 23:42:00 EEST | Press release
The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430693323/en/ The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’ “The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. Anniversary Offerings and Experiences To mark its 95th anniversary, the Empire State Building will debut new experiences
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis30.4.2026 23:17:00 EEST | Press release
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC). MH002 today is the most advanced LBP targeting inflammatory bowel disease (IBD)-specific mechanisms and is composed of a rationally designed microbial consortium of six well-characterized commensal strains. The FDA’s Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important drugs to patients earlier. Fast Track designation enables frequent communication with the FDA to discuss the drug's development plan and ensure collection o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
